<i>In vitro </i>and <i>in vivo</i> toxicological assessments of <i>Antrodia cinnamomea</i> health food product (Leader <i>Antrodia cinnamomea</i> Capsule)

  • Lin Yu-Hsing
    Taiwan Leader Biotech Corp, Taiwan Department of Biological Science and Technology, China University of Science and Techology, Taiwan
  • Senthil Kumar K.J.
    Department of Forestry, National Chung Hsing University, Taiwan
  • Gokila Vani M.
    Department of Forestry, National Chung Hsing University, Taiwan
  • Liao Jiunn-Wang
    Graduate Institute of Veterinary Pathology, National Chung Hsing University, Taiwan
  • Lin Chin-Chung
    Taiwan Leader Biotech Corp, Taiwan
  • Kuo Jong-Tar
    Department of Biological Science and Technology, China University of Science and Techology, Taiwan
  • Wang Sheng-Yang
    Department of Forestry, National Chung Hsing University, Taiwan Agricultural Biotechnology Center, National Chung-Hsing University, Taiwan Agricultural Biotechnology Research Institute, Taiwan

この論文をさがす

抄録

<p>A unique medicinal mushroom Antrodia cinnamomea has been used for centuries to treat various human diseases. Recent studies revealed its potent pharmacological effects including anti-cancer, anti-inflammation, anti-oxidant, anti-diabetic, neuroprotection and hepatoprotection. The present study was aimed to investigate the toxicological effects of A. cinnamomea health food product “Leader Antrodia cinnamomea Capsule (LACC)” by measuring its genotoxic, oral toxic and teratotoxic effects in vitro and in vivo. Result of Ames test with 5 strains of Salmonella typhimurium shows no sign of increase in the numbers of revertant colonies upon exposure to LACC. Treatment of Chinese Hamster Ovary cells (CHO-K1) with LACC did not affect increase in the frequency of chromosomal aberration in vitro. In addition, treatment with LACC did not affect the proportions of immature to total erythrocytes and the number of micronuclei in the immature erythrocytes of ICR mice. Moreover, acute oral toxicity (14-days single-dose) or prolonged oral toxicity (28- and 90-days repeated oral dose) tests with rats showed that there were no observable adverse effects were found. Furthermore, teratological studies with LACC (500-2500 mg/kg/day) for 20 days, shows no observable segment II reproductive and developmental toxic evidences in pregnant SD rats and their fetus. These toxicological assessments strongly support the safety efficacy of LACC for human consumption.</p>

収録刊行物

参考文献 (11)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ